Abstract
We tried to assess the long-term safety and potential efficacy of passive immunization in AIDS-related-complex (ARC) and AIDS patients. We also wanted to establish whether hyperimmune plasma from healthy human immunodeficiency virus 1 (HIV-1)-infected individuals clears the cell-free virus from circulation. Using the polymerase chain reaction (PCR), we were able to provide conclusive evidence that hyperimmune plasma is effective and maintains long-term neutralization of viremia. Using the cell test, we found that in most patients the total antibody level was maintained; in one of the ARC patients, it actually increased 8-fold and has remained at that level for nearly 2 years. The CD4+ cell count decreased in the AIDS patients but was stable in the ARC patient. Clinically, there was an initial improvement in all patients, but five of six of the advanced/terminal AIDS patients had died by month 17. Our studies suggest that passive immunization may be safe in ARC and AIDS patients. It reduces HIV-1 viremia to levels undetectable even by PCR. To advanced/terminal patients, the benefit is of limited duration, while to ARC patients it may be long-term. Therefore, passive immunization should start early in the disease.
MeSH Terms
AIDS-Related Complex/immunology,microbiology
Acquired Immunodeficiency Syndrome/immunology,microbiology
CD4 Antigens/analysis
DNA, Viral/blood,isolation & purification
HIV Antibodies/analysis
HIV Antigens/analysis
HIV-1/genetics,immunology,isolation & purification
Humans
Immunization, Passive
Polymerase Chain Reaction/methods
RNA, Viral/blood,isolation & purification
T-Lymphocytes, Helper-Inducer/immunology
Chemicals
CD4 Antigens
DNA, Viral
HIV Antibodies
HIV Antigens
RNA, Viral
Authors & Affiliations
10 authors, click to expand affiliations / ORCID
Karpas A
Department of Haematology, Cambridge University Clinical School, United Kingdom.
Hewlett I K
Hill F
Gray J
Byron N
Gilgen D
Bally V
Oates J K
Gazzard B
Epstein J E
References (24)
24 references, click to expand
-
Selective tropism of lymphadenopathy associated virus (LAV) for helper-inducer T lymphocytes.
Science. 1984 Jul 6;225(4657):59-63
PMID: 6328660
-
Passive immunization in ARC and AIDS.
Biotherapy. 1990;2(2):159-72
PMID: 2144762
-
Neutralization of human T-lymphotropic virus type III by sera of AIDS and AIDS-risk patients.
Nature. 1985 Jul 4-10;316(6023):69-72
PMID: 2989706
-
HTLV-III-neutralizing antibodies in patients with AIDS and AIDS-related complex.
Nature. 1985 Jul 4-10;316(6023):72-4
PMID: 2989707
-
Lytic infection by British AIDS virus and development of rapid cell test for antiviral antibodies.
Lancet. 1985 Sep 28;2(8457):695-7
PMID: 2863680
-
Human immunodeficiency virus neutralizing antibodies recognize several conserved domains on the envelope glycoproteins.
J Virol. 1987 Jun;61(6):2024-8
PMID: 2437327
-
Effect of immunization with a vaccinia-HIV env recombinant on HIV infection of chimpanzees.
Nature. 1987 Aug 20-26;328(6132):721-3
PMID: 3475581
-
Neutralizing antibodies in HIV (HTLV-III) infection: correlation with clinical outcome and antibody response against different viral proteins.
Clin Exp Immunol. 1987 Aug;69(2):231-9
PMID: 3652531
-
Human immunodeficiency virus type 1 challenge of chimpanzees immunized with recombinant envelope glycoprotein gp120.
Proc Natl Acad Sci U S A. 1988 Jul;85(14):5200-4
PMID: 2455898
-
Failure of a human immunodeficiency virus (HIV) immune globulin to protect chimpanzees against experimental challenge with HIV.
Proc Natl Acad Sci U S A. 1988 Sep;85(18):6944-8
PMID: 3413127
-
Passive immunoneutralization of human immunodeficiency virus in patients with advanced AIDS.
Lancet. 1988 Sep 17;2(8612):647-52
PMID: 2901518
-
Zidovudine and bone marrow.
Lancet. 1988 Nov 19;2(8621):1195-6
PMID: 2903403
-
Infection and replication of HIV-1 in purified progenitor cells of normal human bone marrow.
Science. 1988 Nov 11;242(4880):919-22
PMID: 2460922
-
Effects of zidovudine in 365 consecutive patients with AIDS or AIDS-related complex.
Lancet. 1988 Dec 3;2(8623):1297-302
PMID: 2904016
-
Aminosugar derivatives as potential anti-human immunodeficiency virus agents.
Proc Natl Acad Sci U S A. 1988 Dec;85(23):9229-33
PMID: 3264071
-
Effects of passive immunization in patients with the acquired immunodeficiency syndrome-related complex and acquired immunodeficiency syndrome.
Proc Natl Acad Sci U S A. 1988 Dec;85(23):9234-7
PMID: 3194422
-
Incubation period of AIDS in San Francisco.
Nature. 1989 Mar 16;338(6212):251-3
PMID: 2922052
-
Quantitation of human immunodeficiency virus type 1 in the blood of infected persons.
N Engl J Med. 1989 Dec 14;321(24):1621-5
PMID: 2586564
-
Plasma viremia in human immunodeficiency virus infection.
N Engl J Med. 1989 Dec 14;321(24):1626-31
PMID: 2511447
-
Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT).
Science. 1989 Dec 1;246(4934):1155-8
PMID: 2479983
-
A formalin-inactivated whole SIV vaccine confers protection in macaques.
Science. 1989 Dec 8;246(4935):1293-7
PMID: 2555923
-
The opportunistic tumors of immune deficiency.
Adv Cancer Res. 1990;54:301-17
PMID: 2404381
-
Rational design of peptide-based HIV proteinase inhibitors.
Science. 1990 Apr 20;248(4953):358-61
PMID: 2183354
-
Lymphadenopathy-associated viral antibody in AIDS. Immune correlations and definition of a carrier state.
N Engl J Med. 1984 Nov 15;311(20):1269-73
PMID: 6092953